23rd European Society of Retina Specialists (EURETINA) Congress: 60-week and 2-year (96-weeks) data from Phase 3 PULSAR (nAMD) study

Oct 52023 Oct 5, 2023

These slides contain the 60-week and 2-year (96-weeks) results from the Phase 3 PULSAR study of aflibercept 8 mg for nAMD. The presentation was given by Dr. Paolo Lanzetta at the 23rd EURETINA Congress on October 5, 2023.

Supporting Materials